Skip to content
Catalyst

beta-cryptoxanthinWhat was measured

Measured, with no finding

77 endpoints

Show what was measuredHide what was measured
  • bone turnover markers

    decreases

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers

    PMID 24909799 · one of two readings recorded this

  • HDL cholesterol (c-HDL)

    decreases

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers

    PMID 24909799 · one of two readings recorded this

  • LDL cholesterol (c-LDL)

    decreases

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers

    PMID 24909799 · one of two readings recorded this

  • order of intervention, previous treatment and their interaction (carryover)

    no effect

    Intervention caused changes in almost all the markers while the order, previous treatment and the interaction did not reach statistical significance

    PMID 24909799 · one of two readings recorded this

  • serum β-cryptoxanthin, β-sitosterol and campesterol

    increases

    The intake of beverages containing β-Cx and PS brought about a significant increase in serum levels of β-Cx, β-sitosterol and campesterol

    PMID 24909799 · one of two readings recorded this

  • total cholesterol, c-HDL, c-LDL and bone turnover markers after beverage with beta-cryptoxanthin (0.75 mg/day) and phytosterols (1.5 g/day), single and combined, crossover

    decreases, n = 38

    Not recorded as a finding: the intervention held more than the compound

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers.

    PMID 24909799 · one of two readings recorded this

  • total cholesterol, HDL-cholesterol, LDL-cholesterol and bone turnover markers after 4 weeks of beverage (abstract only)

    decreases, significant decreases in total cholesterol, HDL-cholesterol, LDL-cholesterol and bone turnover markers with the combined beverage only

    Not recorded as a finding: the intervention held more than the compound

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers.

    PMID 24909799 · one of two readings recorded this

  • total cholesterol

    decreases

    Only the intake of the beverage containing β-Cx plus PS brought about significant decreases in total cholesterol, c-HDL, c-LDL and bone turnover markers

    PMID 24909799 · one of two readings recorded this

  • increase of post-practice salivary α-amylase activity

    decreases

    In the β-CRX-group, the increase of post-practice sAA was suppressed in females

    PMID 27592828 · one of two readings recorded this

  • salivary α-amylase activity, post-practice (evening) versus pre-practice (morning)

    increases

    In the placebo-group, sAA in the evening (post-practice sAA) tended to be higher than sAA in the morning (pre-practice sAA) during both routine daily life at the university and during pharmacy practice

    PMID 27592828 · one of two readings recorded this

  • anti-stress effect dose-dependency in stress-loaded male mice

    modulates

    The dose-dependency of β-CRX was observed in male mice that were loaded with stress

    PMID 31366875 · one of two readings recorded this

  • salivary α-amylase activity, evening versus morning, during pharmacy practice

    no effect

    Salivary α-amylase activity (sAA), a marker of sympathetic nervous system activity, was significantly higher in the evening than in the morning in the placebo-group during pharmacy practice, but not in the β-CRX-group

    PMID 31366875 · one of two readings recorded this

  • salivary α-amylase activity, evening versus morning, during pharmacy practice

    increases

    Salivary α-amylase activity (sAA), a marker of sympathetic nervous system activity, was significantly higher in the evening than in the morning in the placebo-group during pharmacy practice, but not in the β-CRX-group

    PMID 31366875 · one of two readings recorded this

  • adiponectin, 12-week change, HPD-BCX versus control

    increases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • high-sensitivity C-reactive protein, 12-week change, HPD-BCX versus control

    decreases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • interleukin-6, 12-week change, HPD-BCX versus control

    decreases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • malondialdehyde, 12-week change, HPD-BCX versus control

    decreases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • serum malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity and adiponectin, HPD-BCX group versus control, 12 weeks

    Not recorded as a finding: the intervention held more than the compound

    These results show that an energy-restricted HPD supplemented with BCX more efficaciously alleviates oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet.

    PMID 31841744 · one of two readings recorded this

  • serum malondialdehyde, hs-CRP, interleukin-6, total cytokeratin-18 (CK18-M65), total antioxidant capacity and adiponectin, 12-week change (abstract only)

    decreases

    Not recorded as a finding: the intervention held more than the compound

    These results show that an energy-restricted HPD supplemented with BCX more efficaciously alleviates oxidative stress and inflammation in NAFLD as compared to a standard energy-restricted diet.

    PMID 31841744 · one of two readings recorded this

  • total antioxidant capacity, 12-week change, HPD-BCX versus control

    increases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • total cytokeratin-18 (CK18-M65), 12-week change, HPD-BCX versus control

    decreases, p = 0.001

    mean differences for malondialdehyde, high-sensitivity C-reactive protein, interleukin-6, total cytokeratin-18, total antioxidant capacity, and adiponectin were -1.9 nmol/mL, -1.0 mg/L, -2.0 ng/L, -270.9 ng/L, 2.5 U/mL, and 1.9 mg/L, respectively; all P < .001

    PMID 31841744 · one of two readings recorded this

  • adherence, number of patients taking at least 90% of prescribed capsules

    no effect, p = 0.956, n = 92

    Adherence (taking ≥ 90% of prescribed capsules) | 84 (91.3) | 22 (95.7) | 20 (87.0) | 21 (91.3) | 21 (91.3) | 0.956

    PMID 33081717 · one of two readings recorded this

  • adverse events, gastrointestinal discomfort or headache, patient report

    no effect, no significant differences in drop-out, adherence and adverse events among study groups

    Not recorded as a finding: the sentence is agentless about the compound and compares all four arms together, with no β-cryptoxanthin-versus-control contrast

    There were no significant differences in drop-out, adherence, and adverse events among study groups.

    PMID 33081717 · one of two readings recorded this

  • change in serum ALP

    decreases, p = 0.005

    Multivariable adjusted | − 56.8 [− 70.6; − 43.0] | − 43.9 [− 58.3; − 29.4] | − 30.7 [− 44.7; − 16.7] | − 17.6 [− 31.8; − 3.4] | 0.005

    PMID 33081717 · one of two readings recorded this

  • change in serum ALP

    decreases, p = 0.001

    Unadjusted | − 57.9 [− 76.0; − 39.9] | − 47.7 [− 68.5; − 26.9] | − 27.1 [− 35.3; − 18.9] | − 16.2 [− 23.2; − 9.3] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • change in serum ALT

    decreases, p = 0.001

    Multivariable adjusted | − 45.7 [− 49.9; − 41.6] | − 35.2 [− 39.5; − 30.8] | − 28.1 [− 32.4; − 23.9] | − 18.5 [− 22.8; − 14.2] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • change in serum ALT

    decreases, p = 0.001

    Unadjusted | − 45.3 [− 50.2; − 40.3] | − 34.6 [− 39.2; − 30.1] | − 28.9 [− 35.0; − 22.8] | − 18.7 [− 23.7; − 13.7] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • change in serum AST

    decreases, p = 0.014

    Multivariable adjusted | − 20.2 [− 23.0; − 17.4] | − 18.4 [− 21.4; − 15.5] | − 15.3 [− 18.2; − 12.4] | − 13.1 [− 16.0; − 10.2] | 0.014

    PMID 33081717 · one of two readings recorded this

  • change in serum AST

    no effect, p = 0.603

    Unadjusted | − 19.4 [− 25.5; − 13.2] | − 15.9 [− 22.6; − 9.2] | − 17.9 [− 24.3; − 11.4] | − 13.9 [− 19.6; − 8.1] | 0.603

    PMID 33081717 · one of two readings recorded this

  • change in serum GGT

    decreases, p = 0.001

    Multivariable adjusted | − 30.5 [− 33.9; − 27.2] | − 21.7 [− 25.2; − 18.2] | − 19.8 [− 23.2; − 16.4] | − 14.2 [− 17.6; − 10.8] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • change in serum GGT

    decreases, p = 0.001

    Unadjusted | − 31.2 [− 35.2; − 27.1] | − 22.2 [− 27.6; − 16.8] | − 19.5 [− 24.0; − 15.0] | − 13.3 [− 16.6; − 10.0] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • clinical remission rate (grade 0 hepatic steatosis)

    increases, p = 0.001

    82.6% in the HP-diet and β-cryptoxanthin group versus 13.0%, 17.4%, and 0.0% in the HP-diet, β-cryptoxanthin, and control groups, respectively; p < 0.001

    PMID 33081717 · one of two readings recorded this

  • drop-out, number of patients

    no effect, p = 1, n = 92

    Drop-out (discontinuing the intervention) | 6 (6.5) | 1 (4.3) | 2 (8.7) | 2 (8.7) | 1 (4.3) | 1.000

    PMID 33081717 · one of two readings recorded this

  • hepatic steatosis grade 0 remission rate, abdominal ultrasonography

    increases, 17.4% remission in the β-cryptoxanthin group versus 0.0% in control

    Not recorded as a finding: no outcome node for hepatic steatosis; the quoted sentence is an all-group comparison, not a β-cryptoxanthin-only versus control contrast

    In contrast to baseline, there was also a significant difference in terms of hepatic steatosis at study endpoint among groups so that clinical remission rate in the HP-diet and β-cryptoxanthin group was considerably higher than the other groups (82.6% in the HP-diet and β-cryptoxanthin group versus 13.0%, 17.4%, and 0.0% in the HP-diet, β-cryptoxanthin, and control groups, respectively; p < 0.001).

    PMID 33081717 · one of two readings recorded this

  • liver enzymes and grade of hepatic steatosis, within-group reduction

    decreases, p = 0.01

    Pairwise within group comparisons showed significant reduction of serum levels of liver enzymes and grade of hepatic steatosis in all study groups during the 12-week intervention period (all p < 0.010)

    PMID 33081717 · one of two readings recorded this

  • patients with hepatic steatosis grade 1 (mild) at study endpoint

    Grade 1 (mild steatosis) | 4 (17.4) | 18 (78.3) | 16 (69.6) | 13 (56.5)

    PMID 33081717 · one of two readings recorded this

  • patients with hepatic steatosis grade 2 (moderate) at study endpoint

    Grade 2 (moderate steatosis) | 0 (0.0) | 2 (8.7) | 3 (13.0) | 10 (43.5)

    PMID 33081717 · one of two readings recorded this

  • serum ALP, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction

    decreases

    for ALP: mean difference − 39.2 IU/L

    PMID 33081717 · one of two readings recorded this

  • serum ALP

    decreases, p = 0.05

    Multivariable adjusted | 137.1 [123.3; 150.8] | 150.0 [135.5; 164.4] | 163.1 [149.1; 177.2] | 176.2 [162.1; 190.4] | 0.050

    PMID 33081717 · one of two readings recorded this

  • serum ALP

    decreases, p = 0.009

    Unadjusted | 136.1 [112.6; 159.5] | 142.7 [122.2; 163.3] | 167.1 [151.5; 182.7] | 180.6 [161.8; 199.3] | 0.009

    PMID 33081717 · one of two readings recorded this

  • serum ALT, β-cryptoxanthin versus control, adjusted 12-week reduction

    decreases, p = 0.005

    for ALT: mean difference − 9.6 IU/L; p = 0.005

    PMID 33081717 · one of two readings recorded this

  • serum ALT, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction

    decreases

    for ALT: mean difference − 27.2 IU/L

    PMID 33081717 · one of two readings recorded this

  • serum ALT, HP-diet versus control, adjusted 12-week reduction

    decreases, p = 0.05

    for ALT: mean difference − 16.6 IU/L; and for GGT: mean difference − 7.5 IU/L; both p < 0.050

    PMID 33081717 · one of two readings recorded this

  • serum ALT

    decreases, p = 0.001

    Multivariable adjusted | 25.1 [21.0; 29.3] | 35.7 [31.3; 40.1] | 42.7 [38.5; 47.0] | 52.4 [48.1; 56.6] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • serum ALT

    decreases, p = 0.001

    Unadjusted | 25.7 [20.9; 30.5] | 36.0 [30.2; 41.8] | 42.6 [37.9; 47.4] | 51.6 [47.6; 55.6] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • serum AST, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction

    decreases

    for AST: mean difference − 7.2 IU/L

    PMID 33081717 · one of two readings recorded this

  • serum AST

    decreases, p = 0.039

    Multivariable adjusted | 18.9 [16.1; 21.7] | 20.7 [17.7; 23.6] | 23.8 [20.9; 26.7] | 26.0 [23.2; 28.9] | 0.039

    PMID 33081717 · one of two readings recorded this

  • serum AST

    no effect, p = 0.121

    Unadjusted | 20.0 [17.5; 22.4] | 21.6 [19.8; 23.4] | 23.1 [21.0; 25.2] | 24.7 [20.2; 29.2] | 0.121

    PMID 33081717 · one of two readings recorded this

  • serum β-cryptoxanthin

    no effect, p = 0.943

    Baseline | 0.16 [0.14; 0.18] | 0.16 [0.14; 0.18] | 0.15 [0.13; 0.17] | 0.16 [0.14; 0.18] | 0.943

    PMID 33081717 · one of two readings recorded this

  • serum β-cryptoxanthin

    increases, p = 0.001

    Week 12 | 0.28 [0.25; 0.30] | 0.16 [0.14; 0.18] | 0.26 [0.23; 0.29] | 0.16 [0.14; 0.18] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • serum GGT, HP-diet and β-cryptoxanthin versus control, adjusted 12-week reduction

    decreases

    for GGT: mean difference − 16.3 IU/L

    PMID 33081717 · one of two readings recorded this

  • serum GGT, HP-diet versus control, adjusted 12-week reduction

    decreases, p = 0.05

    for ALT: mean difference − 16.6 IU/L; and for GGT: mean difference − 7.5 IU/L; both p < 0.050

    PMID 33081717 · one of two readings recorded this

  • serum GGT

    decreases, p = 0.001

    Multivariable adjusted | 16.9 [13.5; 20.2] | 25.7 [22.2; 29.2] | 27.6 [24.2; 31.0] | 33.2 [29.7; 36.6] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • serum GGT

    decreases, p = 0.001

    Unadjusted | 17.0 [14.3; 19.7] | 25.5 [21.8; 29.2] | 27.8 [24.4; 31.2] | 33.0 [29.8; 36.3] | < 0.001

    PMID 33081717 · one of two readings recorded this

  • weight loss as percent of baseline weight

    decreases, p = 0.001

    the corresponding values in the other groups (i.e., 3.9% in both β-cryptoxanthin and control groups) were significantly lower (all p < 0.001)

    PMID 33081717 · one of two readings recorded this

  • weight loss as percent of baseline weight

    decreases

    patients in the HP-diet and β-cryptoxanthin and HP-diet groups had lost 6.8% and 6.9% of their baseline weight at study endpoint respectively

    PMID 33081717 · one of two readings recorded this

  • depression, stress and anxiety scores

    no effect

    No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed

    PMID 37242207 · one of two readings recorded this

  • gastrointestinal discomfort or headache

    no effect

    No gastrointestinal discomfort or headache was reported

    PMID 37242207 · one of two readings recorded this

  • gene expression of RARA, RXRA, RXRB, BHLHE40, PPARD and ALDH1A1

    no effect

    Overall, 8 weeks of supplementation of β-cryptoxanthin up to 6 mg/day did not significantly change the gene expression of RARA, RXRA, RXRB, BHLHE40, PPARD, and ALDH1A1 in PBMCs

    PMID 37242207 · one of two readings recorded this

  • gut microbial community diversity

    no effect

    There was no significant difference in microbial community diversity between the samples of the three different treatment groups before and after supplementation

    PMID 37242207 · one of two readings recorded this

  • gut microbial composition

    no effect

    Overall, the results indicated that β-cryptoxanthin consumption of up to 6 mg/day had no significant effect on microbial composition compared with placebo

    PMID 37242207 · one of two readings recorded this

  • mean compliance rate

    The mean compliance rate was 95%

    PMID 37242207 · one of two readings recorded this

  • physical activity and sleep patterns

    no effect

    No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed

    PMID 37242207 · one of two readings recorded this

  • plasma beta-cryptoxanthin concentration at 2, 4 and 8 weeks, HPLC, 3 and 6 mg/day versus placebo (primary outcome); other endpoints read and left without a node or without a self-supporting between-arm sentence: plasma other carotenoids and retinol, PBMC retinol-signalling gene expression by qPCR, fecal microbiome 16S, GHQ12/QLES/STAI/DASS/PSS, accelerometer activity and PSQI sleep, safety laboratory panel

    increases

    Not recorded as a finding: this platform holds no node for the endpoint

    At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001).

    PMID 37242207 · one of two readings recorded this

  • plasma α-carotene concentration

    increases

    0.26 ± 0.43 µmol/L at week 8 vs. 0.09 ± 0.04 µmol/L at baseline for placebo

    PMID 37242207 · one of two readings recorded this

  • plasma α-cryptoxanthin, β-carotene, lycopene, lutein, zeaxanthin and all-trans retinol concentrations

    no effect

    The mean plasma concentrations of the other carotenoids (α-cryptoxanthin, β-carotene, lycopene, lutein, and zeaxanthin) and all-trans retinol did not change with time in all three groups

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration, HPLC, at 2, 4 and 8 weeks (primary outcome); also plasma α-cryptoxanthin, α-carotene, β-carotene, lycopene, lutein, zeaxanthin and all-trans retinol by HPLC; PBMC retinol-signalling gene expression by qPCR; GHQ12, QLES, SWLS, STAI, DASS, PSS; actigraphy and PSQI; gut microbiome 16S

    increases, significantly higher than control at 4 and 8 weeks in both the 3 and 6 mg/day groups

    Not recorded as a finding: this platform holds no node for the endpoint

    At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001).

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases, p = 0.001

    At 4 and 8 weeks, the concentration of β-cryptoxanthin in the 3 and 6 mg/day groups were significantly higher compared to the control (p < 0.001)

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases, p = 0.03

    Further, the concentration of β-cryptoxanthin in the 6 mg/day group was significantly higher compared to that in the 3 mg/day group (p = 0.03)

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases

    Following 2 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration increased to 3.5 ± 1.6 µmol/L from a baseline of 0.6 ± 0.5 µmol/L in the 3 mg/day group

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases

    After 8 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration further increased to 6.0 ± 2.6 µmol/L in the 3 mg/day group and to 9.0 ± 4.1 µmol/L in the 6 mg/day group

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases

    and to 4.2 ± 1.2 µmol/L from a baseline of 0.4 ± 0.2 µmol/L in the 6 mg/day group

    PMID 37242207 · one of two readings recorded this

  • plasma β-cryptoxanthin concentration

    increases

    After 8 weeks of daily consumption of β-cryptoxanthin, the plasma β-cryptoxanthin concentration further increased to 6.0 ± 2.6 µmol/L in the 3 mg/day group and to 9.0 ± 4.1 µmol/L in the 6 mg/day group

    PMID 37242207 · one of two readings recorded this

  • quality-of-life scores

    no effect

    No significant alterations in quality-of-life scores, depression, stress and anxiety scores, and physical activity and sleep patterns were observed

    PMID 37242207 · one of two readings recorded this

  • serious or severe adverse events and deaths

    no effect

    No serious or severe adverse events or deaths were observed

    PMID 37242207 · one of two readings recorded this

  • study completion

    n = 80

    Overall, 89% of all randomized participants (n = 80) completed the study

    PMID 37242207 · one of two readings recorded this

  • vital signs and laboratory parameters

    no effect

    No clinically significant changes in vital signs or laboratory parameters that were considered to be related to β-cryptoxanthin were observed after 8 weeks of supplementation of up to 6 mg/day

    PMID 37242207 · one of two readings recorded this